XT
NTLA icon

XTX Topco’s Intellia Therapeutics NTLA Stock Holding History

XTX Topco’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.41M Buy
201,436
+147,454
+273% +$2.06M 0.04% 637
2026
Q1 		$692K Buy
53,982
+9,219
+21% +$117K 0.01% 1734
2025
Q4 		$402K Buy
+44,763
New +$616K 0.01% 1813
2025
Q3 		– Sell
-41,639
Closed -$391K – 3046
2025
Q2 		$391K Sell
41,639
-39,258
-49% -$322K 0.02% 1273
2025
Q1 		$575K Buy
80,897
+36,989
+84% +$374K 0.03% 924
2024
Q4 		$512K Buy
43,908
+29,006
+195% +$453K 0.04% 753
2024
Q3 		$306K Sell
14,902
-35,562
-70% -$820K 0.02% 1166
2024
Q2 		$1.13M Buy
50,464
+32,201
+176% +$767K 0.1% 311
2024
Q1 		$502K Buy
18,263
+5,642
+45% +$157K 0.07% 484
2023
Q4 		$385K Sell
12,621
-2,255
-15% -$64.8K 0.08% 428
2023
Q3 		$470K Buy
+14,876
New +$577K 0.08% 439
2023
Q2 		– Sell
-13,258
Closed -$494K – 1701
2023
Q1 		$494K Buy
13,258
+55
+0.4% +$2.16K 0.1% 300
2022
Q4 		$461K Buy
13,203
+1,796
+16% +$85.4K 0.1% 340
2022
Q3 		$638K Buy
+11,407
New +$708K 0.16% 147
2021
Q3 		– Sell
-2,762
Closed -$447K – 945
2021
Q2 		$447K Buy
+2,762
New +$215K 0.15% 218

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

XTX Topco's NTLA Position: Q2 2026 in Review

XTX Topco increased its Intellia Therapeutics (NTLA) stake by 273% in Q2 2026, buying an estimated $2.06M and bringing the position to 201,436 shares worth $3.41M. The position accounts for 0.04% of the portfolio, ranked #637.

XTX Topco first reported a position in NTLA in Q2 2021 and has held it in 15 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • XTX Topco held 201,436 shares of Intellia Therapeutics worth $3.41M as of Q2 2026.
  • XTX Topco bought 147,454 Intellia Therapeutics shares in Q2 2026, an estimated $2.06M.
  • Intellia Therapeutics made up 0.04% of XTX Topco's portfolio in Q2 2026, its #637 holding.
  • XTX Topco first reported a position in Intellia Therapeutics in Q2 2021 and has held it in 15 quarters since.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.